ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Abstract: PO2074

Mortality, Graft Survival, and Cardiovascular Outcomes in Adult Kidney Transplant Recipients with Post-Transplant Anemia: An Updated Meta-Analysis

Session Information

Category: Transplantation

  • 1902 Transplantation: Clinical

Authors

  • Mekraksakit, Poemlarp, Texas Tech University Health Sciences Center, Lubbock, Texas, United States
  • Leelaviwat, Natnicha, Texas Tech University Health Sciences Center, Lubbock, Texas, United States
  • Boonpheng, Boonphiphop, University of California Los Angeles David Geffen School of Medicine, Los Angeles, California, United States
  • Cheungpasitporn, Wisit, Mayo Clinic Minnesota, Rochester, Minnesota, United States
  • Pena, Camilo, Texas Tech University Health Sciences Center, Lubbock, Texas, United States
  • Del Rio-Pertuz, Gaspar, Texas Tech University Health Sciences Center, Lubbock, Texas, United States
  • Saxena, Ramesh, The University of Texas Southwestern Medical Center, Dallas, Texas, United States
Background

Post-transplant anemia (PTA) is a common finding after kidney transplantation. A previous meta-analysis reported an association between PTA and graft loss. However, data on cardiovascular outcomes have not yet been reported. We conducted an updated meta-analysis to examine the association between PTA and prognosis in adult kidney transplant recipients.

Methods

We comprehensively searched the databases of MEDLINE and EMBASE from inception to January 2021. Data from each study were combined using the random-effects model.

Results

Seventeen studies from August 2006 to April 2019 were included (16,463 KT recipients). The PTA was associated with overall mortality (pooled RR=1.72 [1.39, 2.13], I2=56%), graft failure (pooled RR=2.28 [1.77, 2.93], I2=94%), cardiovascular death (pooled RR=2.06 [1.35, 3.16], I2=0%), and cardiovascular events (pooled RR=1.33 [1.10, 1.61], I2=0%). Early PTA (≤ 6 months), compared with late PTA (> 6 months), has higher risk of overall mortality and graft loss with a pooled risk ratio of 2.63 (95% CI 1.79-3.86, I2=0%) and 2.96 (95% CI 2.29-3.82, I2=0%), respectively.

Conclusion

Our meta-analysis demonstrates that PTA was significantly associated with overall mortality, graft failure, cardiovascular death, and cardiovascular events.

The association between PTA and overall mortality

The association between PTA and graft loss